Eradication of H-pylori in Pregnancy and Its Effect on Iron Replacement Therapy?

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE4

Total Enrollment

150 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-11-25

Study Completion Date

2019-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

the effect of eradication of H-pylori in pregnant patients with iron deficiency anemia on the level of hemoglobin after iron therapy.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Effects of Dietary Heme/Non-heme Iron and Helicobacter Pylori (Hp) Infection on Maternal Iron-deficiency Anemia and Fetal Growth Outcomes

NCT01071759

Pregnancy Helicobacter Pylori Infection Iron-Deficiency Anemia

UNKNOWN

Helicobacter Pylori and Proton Pump Inhibitor

NCT02449941

Helicobacter Infections

COMPLETED

The Effect of H. Pylori Infection on Iron Metabolism

NCT00202488

Iron Deficiency Anemia Helicobacter Pylori Infection

COMPLETED PHASE2/PHASE3

Is Helicobacter Pylori Infection a Cause or Treatment Failure of Iron Deficiency Anemia in Children in Bangladesh?

NCT00284700

Helicobacter Pylori Infection Iron Deficiency Anemia Not Severely Malnourished +2 more

COMPLETED NA

Helicobacter Pylori Screening at Sohag University

NCT05835076

In Early Pregnancy

UNKNOWN

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

After approval of the "Ethics Committee" of the obstetrics and gynecology department of the faculty of medicine Cairo University, a clinical trial will be started in which pregnant patients with iron deficiency anemia will be recruited out of the antenatal care clinic. Routine complete blood count (CBC) is done early during the second trimester for cases with anemia discovered by labs drawn on their booking appointment during their 1st antenatal care visit.

IDA defined as hemoglobin below 11gm/dl with MCV below 80 fl, with one of the following: if the serum ferritin level is below 70 μg/L. or if transferrin saturation is below 20.

We based our sample size according to the work done by Nashaat \& Mansour, 2014 who studied a difference in the mean hemoglobin level of 1.6 g/dl with a standard deviation of 3.3. The ratio of women in the control group to experimental group was set at 1:1, the power at 0.8, and the type I error at 0.05 which gave us 68 subjects in every arm. We allowed for 10% dropouts finally giving us 75 subjects on each study arm.

After obtaining informed consent, H-pylori infection will be diagnosed using a stool antigen assay ABON which is one step H. pylori antigen test device (®Inverness Medical Innovation Hong Kong Limited). A stool sample will be collected and the top screwed on. An applicator will then be introduced into the sample after unscrewing of the cap in three different sites to collect at least 50 mg of fecal matter. The sample will be centrifuged at 4000 rpm for 5 minutes and the supernatant will be used for immunoassay. Two drops will be placed on the kit as per kit instructions. This test utilizes lateral chromatographic assay where after 10 minutes a positive sample will have a purple-pink line in addition to the control line, while a negative test only has the control line present. If the control line was missing the test will be considered invalid.

All the enrolled participants will then be randomized into two groups using a computer generated randomization table and a sealed envelope system to be opened by the nurse in the next antenatal care visit. When the envelope is opened the participant will be assigned to either group (A) (eradication of H-pylori before iron therapy) or group (B) (start iron therapy without eradication o f H-pylori).

Participants in group A will undergo eradication of H-pylori using triple attack therapy according to O'Connor et al, 2013 with Proton pump inhibitor (eg, omeprazole 20 mg BID), Clarithromycin 500 mg BID, metronidazole 500 mg BID for 14 days, followed by confirmation of eradication by repeating the H-pylori stool antigen test .

Iron therapy will be given to both groups twice daily for one month in the form ferrous(II)-glycine-sulphate complex 567.7 mg capsules (each capsule contains about 100 mg elemental iron) Ferro sanol duodenal ®Minapharm , Egypt. All recruited cases will undergo blood sampling for complete blood count (CBC), serum ferritin, transferrin saturation, and total iron binding capacity (TIBC) before and after iron therapy. All demographic data along with relevant history taking and examination will be recorded at the beginning of recruitment including age, body mass index (BMI), and parity e.t.c.

PS Power and Sample Size Calculations software, version 2.1.30 for MS Windows, was used to calculate sample size (Dupont and Vanderbilt, Nashville, TN).

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pregnancy Complications Anemia, Iron Deficiency H Pylori Infection

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Randomized controlled trial

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Eradication of H-pylori

triple attack therapy (Clarithromycin 500 mg BID for 14 days, omeprazole 20 mg BID for 14 days, metronidazole 500 mg BID for 14 days).

Followed by confirmation of eradication by repeating the H-pylori stool antigen test.

Iron therapy will be given twice daily for one month in the form ferrous(II)-glycine-sulphate complex 567.7 mg capsules (each capsule contains about 100 mg elemental iron) Ferro sanol duodenal ®Minapharm, Egypt.

Group Type EXPERIMENTAL

triple attack therapy

Intervention Type DRUG

eradication of H-pylori using triple attack therapy.

Ferrous(II)-glycine-sulphate complex 567.7 mg capsules

Intervention Type DRUG

Iron therapy will be given to both groups twice daily for one month.

No eradication of H-pylori

Iron therapy will be given twice daily for one month in the form ferrous(II)-glycine-sulphate complex 567.7 mg capsules (each capsule contains about 100 mg elemental iron) Ferro sanol duodenal ®Minapharm, Egypt.

Group Type ACTIVE_COMPARATOR

Ferrous(II)-glycine-sulphate complex 567.7 mg capsules

Intervention Type DRUG

Iron therapy will be given to both groups twice daily for one month.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

triple attack therapy

eradication of H-pylori using triple attack therapy.

Intervention Type DRUG

Ferrous(II)-glycine-sulphate complex 567.7 mg capsules

Iron therapy will be given to both groups twice daily for one month.

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

KLACID XL 500 mg HEALSEC 20 mg Flagyly 500 mg Ferro sanol duodenal ®Minapharm , Egypt

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Diagnosed Iron deficiency anemia.
* H-pylori positive cases.
* Second trimester pregnancy.

Exclusion Criteria

* Severe Iron deficiency anemia (hemoglobin \< 8.0 g/dL).
* Parasitic worm infection e.g. schistosomiasis, and hook worm by stool analysis.
* Any cases giving clinical symptoms of gastritis e.g. nausea, vomiting, dull aching pain or soreness in the epigastrium.
* Cases with history of gastric ulcer diagnosed by upper endoscopy.
* Cases complaining of hematemesis.

Maximum Eligible Age

40 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

Yes